IL311578A - Lyophilized enpp1 polypeptide formulations and uses thereof - Google Patents
Lyophilized enpp1 polypeptide formulations and uses thereofInfo
- Publication number
- IL311578A IL311578A IL311578A IL31157824A IL311578A IL 311578 A IL311578 A IL 311578A IL 311578 A IL311578 A IL 311578A IL 31157824 A IL31157824 A IL 31157824A IL 311578 A IL311578 A IL 311578A
- Authority
- IL
- Israel
- Prior art keywords
- lyophilized
- polypeptide formulations
- enpp1 polypeptide
- enpp1
- formulations
- Prior art date
Links
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 title 1
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248303P | 2021-09-24 | 2021-09-24 | |
| PCT/US2022/076969 WO2023049864A1 (en) | 2021-09-24 | 2022-09-23 | Lyophilized enpp1 polypeptide formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311578A true IL311578A (en) | 2024-05-01 |
Family
ID=85721287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311578A IL311578A (en) | 2021-09-24 | 2022-09-23 | Lyophilized enpp1 polypeptide formulations and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250073319A1 (https=) |
| EP (1) | EP4404980A4 (https=) |
| JP (1) | JP2024536821A (https=) |
| KR (1) | KR20240064707A (https=) |
| CN (1) | CN118215507A (https=) |
| AU (1) | AU2022353101A1 (https=) |
| CA (1) | CA3231858A1 (https=) |
| CO (1) | CO2024004755A2 (https=) |
| IL (1) | IL311578A (https=) |
| MX (1) | MX2024003506A (https=) |
| TW (1) | TW202330017A (https=) |
| WO (1) | WO2023049864A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4414028A3 (en) * | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| US12134790B2 (en) * | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| CA3126839A1 (en) * | 2019-01-18 | 2020-07-23 | Inozyme Pharma, Inc. | Treatment of diseases involving deficiency of enpp1 or enpp3 |
| CA3195071A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
-
2022
- 2022-09-23 CA CA3231858A patent/CA3231858A1/en active Pending
- 2022-09-23 WO PCT/US2022/076969 patent/WO2023049864A1/en not_active Ceased
- 2022-09-23 TW TW111136212A patent/TW202330017A/zh unknown
- 2022-09-23 EP EP22873898.5A patent/EP4404980A4/en active Pending
- 2022-09-23 JP JP2024518385A patent/JP2024536821A/ja active Pending
- 2022-09-23 AU AU2022353101A patent/AU2022353101A1/en active Pending
- 2022-09-23 MX MX2024003506A patent/MX2024003506A/es unknown
- 2022-09-23 IL IL311578A patent/IL311578A/en unknown
- 2022-09-23 KR KR1020247012631A patent/KR20240064707A/ko active Pending
- 2022-09-23 CN CN202280074276.7A patent/CN118215507A/zh active Pending
-
2024
- 2024-03-21 US US18/612,571 patent/US20250073319A1/en active Pending
- 2024-04-16 CO CONC2024/0004755A patent/CO2024004755A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024004755A2 (es) | 2024-05-10 |
| KR20240064707A (ko) | 2024-05-13 |
| TW202330017A (zh) | 2023-08-01 |
| JP2024536821A (ja) | 2024-10-08 |
| CA3231858A1 (en) | 2023-03-30 |
| US20250073319A1 (en) | 2025-03-06 |
| EP4404980A4 (en) | 2025-11-19 |
| MX2024003506A (es) | 2024-04-23 |
| EP4404980A1 (en) | 2024-07-31 |
| CN118215507A (zh) | 2024-06-18 |
| WO2023049864A1 (en) | 2023-03-30 |
| AU2022353101A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279897A (en) | Fusosome compositions and uses thereof | |
| IL286717A (en) | Immunotherapeutic compositions and use thereof | |
| EP3618871A4 (en) | FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | |
| IL311339A (en) | Gelma polymer compositions and uses thereof | |
| DK3660146T3 (da) | Ydelsesforbedrede og opbevaringsstabile proteasevarianter | |
| EP4204751A4 (en) | FREEZE-DRYING SYSTEMS AND PROCESSES | |
| IL283942A (en) | Tubulysins and protein-tubulysin conjugates | |
| EP3976630A4 (en) | Actrii-binding proteins and uses thereof | |
| IL312330A (en) | Tyk2 degraders and uses thereof | |
| EP3678687A4 (en) | CONJUGATES OF PEPTIDE FGF-21 MUTANT AND THEIR USES | |
| EP4329739A4 (en) | LIPID NANOMATERIALS AND THEIR USES | |
| EP4041410A4 (en) | GENETICALLY MODIFIED TRIMERIC CD70 PROTEINS AND THEIR USES | |
| EP4262750A4 (en) | Protein formulations and uses thereof | |
| IL304607A (en) | Compositions comprising pedf-derived short peptides (pdsp) and uses thereof | |
| EP4136101A4 (en) | GENETICALLY MODIFIED INTERLEUKIN-22 POLYPEPTIDES AND THEIR USES | |
| IL312965A (en) | Immunogenic compositions and their uses | |
| KR102192192B9 (ko) | 보툴리눔 독소 및 세포 투과성 펩타이드를 포함하는 재조합 단백질과 이를 포함하는 화장료 조성물 | |
| EP4323007A4 (en) | Polypeptide formulations | |
| MA55761A (fr) | Formulations et anticorps anti-cd38 | |
| EP4281045A4 (en) | LYOPHILIZED ANTIBODY FORMULATIONS AND RELATED METHODS | |
| MA52021A (fr) | Anticorps anti-lif et leurs formes galéniques | |
| EP4034113A4 (en) | THERAPEUTIC FORMULATIONS AND THEIR USES | |
| EP4323412A4 (en) | Fusion proteins and uses thereof | |
| IL311578A (en) | Lyophilized enpp1 polypeptide formulations and uses thereof | |
| EP4230657A4 (en) | FUSION PROTEIN AND VACCINE |